Mr Politics

Greek Historian. Anthropologist. Philosopher. NYT Best Selling Author. $NWBO shareholder @.26 173,000 shares

[Mr Politics @PrometheusMemo]

😱 MASSIVE UPDATE BNOS PRESENTATION SUMMARY!😱

DCVax-L is starting to look like one of the most misunderstood stories in biotech.

The latest BNOS analysis doesn’t just confirm efficacy — it suggests the Phase 3 trial significantly UNDERSTATED it. #NWBO #DCVAX 💎💎💎

[Carlo Rago, PhD @rago_carlo]

New IPD-based PSM/IPW methods estimate a +3.4 to +6.3-month mOS benefit for DCVax-L in ndGBM across 11 survival analyses. For context, the original JAMA cohort-level analysis showed a +2.8-month mOS benefit — suggesting the original estimate may have been conservative. Importantly, these analyses were anticipated in the SAP.

$NWBO Northwest Biotherapeutics. DCVax-L, an autologous dendritic cell cancer vaccine awaits MHRA decision for glioblastoma. Wave of combination studies anticipated.

https://t.co/MjrUICgKGo

[Peter Kostis @peterjkostis]

This new data suggests that the original survival benefit for DCVax-L was SIGNIFICANTLY UNDERESTIMATED! Makes one question why the approval process is taking so long ?

[Andrew Caravello, DO @andrewcaravello]

$NWBO #DCVax #GBM

[Mr Politics @PrometheusMemo]

DCVax-L isn’t getting weaker with time —
it’s getting stronger as the data is reanalyzed

And the case for approval?

👉 Quietly becoming much harder to ignore

[Mr Politics @PrometheusMemo]

😱 MASSIVE UPDATE BNOS PRESENTATION SUMMARY!😱

DCVax-L is starting to look like one of the most misunderstood stories in biotech.

The latest BNOS analysis doesn’t just confirm efficacy — it suggests the Phase 3 trial significantly UNDERSTATED it. #NWBO #DCVAX 💎💎💎

[Mr Politics @PrometheusMemo]

If that happens, the narrative flips:

From:
“controversial dataset”

To:
“undervalued immunotherapy platform with expansion potential”

[Andrew Caravello, DO @andrewcaravello]

$NWBO Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting. https://t.co/dP59GwVni4

[Athanasius @Athanasius_45]

Plutarch on the reasons for the decline of Sparta:

κατ᾿ ὀλίγον δὲ παραβαινομένων καὶ πλεονεξίας καὶ φιλοπλουτίας παρεισδυομένης, καὶ τὰ τῆς δυνάμεως ἠλαττοῦτο· καὶ οἱ σύμμαχοι διὰ ταῦτα δυσμενῶς εἶχον πρὸς αὐτούς.
-
But gradually, as the laws were transgressed and oaths violated, and greed and a desire for wealth snuck in, the means of their power diminished, and as a consequence their allies started harboring ill-will towards them.
Instituta Laconica 240a

https://t.co/jrCldNDpaW

[Mr Politics @PrometheusMemo]

@LoriMills4CA42 $NWBO DCVax-L is the future

[Richard Fairgrieve @RichFairgrieve]

$NWBO - new trial for ovarian cancer:
https://t.co/3O7hjozvVu

[Mr Politics @PrometheusMemo]

Incoming UK approval and FDA BLA application! Setting up the foundations $nwbo #nwbo #nvda #tsla #spacex

[Mr Politics @PrometheusMemo]

Incoming UK approval and FDA BLA application! Setting up the foundations $nwbo #nwbo #nvda #tsla #spacex

[Parker Institute for Cancer Immunotherapy @parkerici]

Yesterday, PICI convened a congressional briefing on Capitol Hill exploring the transformative potential of cancer vaccines.

We were honored to be joined by cancer vaccine recipients and advocates from across the country, Congresswoman @DWStweets, @TheVinodLab from @MSKCancerCenter, and other leaders committed to advancing research and innovation. Several cancer vaccine recipients and PICI leaders also met with Senator Todd Young to discuss the promise of cancer vaccines and help raise awareness of their potential impact on patients.

Hearing these powerful stories and conversations serves as a reminder of what is possible when scientific innovation, patient advocacy, and public investment come together to drive progress against cancer. PICI is proud to help advance conversations and collaborations needed to bring these promising therapies to more patients.